DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts

Completed

Conditions: Urothelial Carcinoma of the Bladder

Interventions: Other: Blood Collection

First Posted Date: 2014-09-23

Last Posted Date: 2020-12-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 87

Registration Number: NCT02246738

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

Early Phase 1

Completed

Conditions: High Risk MDS or AML Patients

First Posted Date: 2014-09-08

Last Posted Date: 2020-04-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 25

Registration Number: NCT02233504

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

First Posted Date: 2014-08-25

Last Posted Date: 2018-08-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02225002

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer

Phase 1

Active, not recruiting

Conditions: Esophageal Cancer

Interventions: Radiation: 18F-FDG (Fluorodeoxyglucose) PET
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2014-08-11

Last Posted Date: 2025-01-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT02213497

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Phase 1

Recruiting

Conditions: Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy
Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

Interventions: Radiation: Radiotherapy
Drug: Abraxane

First Posted Date: 2014-08-04

Last Posted Date: 2024-11-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 42

Registration Number: NCT02207465

Locations: 🇺🇸
Chester County Hospital, West Chester, Pennsylvania, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Nelfinavir (Viracept®) 1250 mg
Other: Chemoradiation

First Posted Date: 2014-08-04

Last Posted Date: 2023-07-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT02207439

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

Phase 2

Withdrawn

Conditions: B-cell Acute Lymphoblastic Leukemia
Relapsed B-cell Acute Lymphoblastic Leukemia
Refractory B-cell Acute Lymphoblastic Leukemia

Interventions: Drug: CTL019

First Posted Date: 2014-06-19

Last Posted Date: 2017-02-14

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02167360

A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer

Phase 2

Completed

Conditions: Oropharyngeal Cancer

Interventions: Procedure: TORS
Radiation: Adjuvant Radiation Therapy

First Posted Date: 2014-06-10

Last Posted Date: 2019-11-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 60

Registration Number: NCT02159703

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases

Active, not recruiting

Conditions: Neoplastic Disease

Interventions: Other: Data Collection

First Posted Date: 2014-06-10

Last Posted Date: 2024-06-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 400

Registration Number: NCT02159742

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Early Phase 1

Completed

Conditions: Solid Tumors

Interventions: Biological: CP-870,893

First Posted Date: 2014-06-06

Last Posted Date: 2018-08-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT02157831

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy